## Note
nid: 1497203886624
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#B&B::15_Neuro::07_Other::05_Demyelinating_Diseases, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Natalizumab, #AK_Step1_v11::#OME_banner::Basic_Science::07_Immunology, #AK_Step1_v11::#SketchyPharm::Immunology-&-Biochemistry-Pharmacology::Immuno-suppressives::General-Immunotherapy, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::2-RelativelyHighYield
markdown: false

### Text
<div>
  In the treatment of Multiple Sclerosis<b>, Natalizumab</b> works
  by preventing extravasation of autoreactive <b>{{c1::CD8+::CD4 or
  CD8?}} T Cells</b>
</div>

### Extra
<i>VLA4 (which has A4 integrin) binds to the VCAM-1 receptor on the
endothelium</i>
<div>
  <i>This prevents self reactive CD8 + T cells from penetrating the
  BBB</i>
</div>
<div>
  <i><img src="gr1%20(2).jpg"></i>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/immunology?ref=anki"><img src=
  "_OME_AnkiFlashcards_Topic_2.png"></a>
</div>

### Additional Resources


### One by one

